SinoMab BioScience Limited — Board/Management Information 2024

Dec 19, 2024

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SINOMAB

SinoMab BioScience Limited

中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 3681)

CHANGE OF NON-EXECUTIVE DIRECTOR

The board (the "Board") of directors ("Director(s)") of SinoMab BioScience Limited (the "Company", together with its subsidiaries, the "Group") hereby announces that with effect from 19 December 2024:

(1) Mr. Lei SHI ("Mr. Shi") has resigned as a non-executive Director due to his other business commitments; and
(2) Ms. Xiaosu WANG ("Ms. Wang") has been appointed as a non-executive Director.

Mr. Shi confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the "Stock Exchange").

The Board would like to express its gratitude to Mr. Shi for his valuable contribution to the Group during his tenure of service.

The biographical information of Ms. Wang is set out as below:

Xiaosu WANG, aged 43, is currently a securities affairs representative and a director of the office of the board of Hainan Haiyao Co., Ltd. (海南海藥股份有限公司) (listed on the Shenzhen Stock Exchange, stock code: 000566). From June 2007 to February 2012, Ms. Wang served as a securities affairs representative of Shenzhen Infineon Technology Co., Ltd.* (深圳英飛拓科技股份有限公司) (listed on the Shenzhen Stock Exchange, stock code: 002528).

Ms. Wang obtained a Bachelor of Laws degree from Zhongnan University of Economics and Law in 2003. She also obtained the qualification certificate for board secretaries granted by the Shenzhen Stock Exchange in 2012.

• For identification purposes only

---

Save as disclosed above, as at the date of this announcement, Ms. Wang (i) is not interested in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) is independent from and has no relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; (iii) has not held any other major appointments or qualifications or positions with the Company or other members of the Group; and (iv) has not held any directorship in any other listed public companies in the past three years.

The Company will enter into a letter of appointment with Ms. Wang. The initial length of services will commence from the date of appointment for a term of three years, subject to re-election and retirement as required by the articles of association of the Company. Ms. Wang will not receive any remuneration from the Company for being a non-executive Director.

Save as disclosed above, there is no information which is discloseable nor is Ms. Wang involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on the Stock Exchange and there are no other matters concerning Ms. Wang that need to be brought to the attention of the shareholders of the Company.

By Order of the Board

SinoMab BioScience Limited

Dr. Shui On LEUNG

Executive Director, Chairman and Chief Executive Officer

Hong Kong, 19 December 2024

As at the date of this announcement, the executive directors are Dr. Shui On LEUNG and Mr. Shanchun WANG, the non-executive directors are Dr. Haigang CHEN, Mr. Xun DONG, Ms. Xiaosu WANG and Dr. Jianmin ZHANG, and the independent non-executive directors are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.

– 2 –